This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rittenhouse, S.
Right arrow Articles by Payne, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rittenhouse, S.
Right arrow Articles by Payne, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2006, p. 3886-3888, Vol. 50, No. 11
0066-4804/06/$08.00+0     doi:10.1128/AAC.00183-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Use of the Surgical Wound Infection Model To Determine the Efficacious Dosing Regimen of Retapamulin, a Novel Topical Antibiotic

Stephen Rittenhouse,* Christine Singley, Jennifer Hoover, Roni Page, and David Payne

Department of Microbiology, MMPD CEDD, GlaxoSmithKline Pharmaceuticals, Upper Providence, Pennsylvania

Received 10 February 2006/ Returned for modification 19 April 2006/ Accepted 10 July 2006

The effect of topically applied retapamulin ointment was evaluated using various dosing regimens in the Staphylococcus aureus and Streptococcus pyogenes wound infection model. Retapamulin (1%, wt/wt) was efficacious using twice-daily (b.i.d.) applications for 4 or 5 days. These data underpinned the decision to evaluate 1% retapamulin b.i.d. in clinical trials.

* Corresponding author. Mailing address: Department of Microbiology Research, MMPD CEDD, GlaxoSmithKline Pharmaceuticals, 1250 S. Collegeville Rd, Collegeville, PA 19426-0989. Phone: (610) 917-6287. Fax: (610) 917-7901. E-mail: Stephen_Rittenhouse{at}GSK.com.

Antimicrobial Agents and Chemotherapy, November 2006, p. 3886-3888, Vol. 50, No. 11
0066-4804/06/$08.00+0     doi:10.1128/AAC.00183-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Davidovich, C., Bashan, A., Auerbach-Nevo, T., Yaggie, R. D., Gontarek, R. R., Yonath, A. (2007). Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc. Natl. Acad. Sci. USA 104: 4291-4296 [Abstract] [Full Text]  
  • Rittenhouse, S., Biswas, S., Broskey, J., McCloskey, L., Moore, T., Vasey, S., West, J., Zalacain, M., Zonis, R., Payne, D. (2006). Selection of Retapamulin, a Novel Pleuromutilin for Topical Use. Antimicrob. Agents Chemother. 50: 3882-3885 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»